Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Q37774915)

23 August 2017

1 reference

title

Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

23 August 2017

1 reference

Ryuzo Ohno

1

1 reference

23 August 2017

1 October 2010

1 reference

Current hematologic malignancy reports

23 August 2017

1 reference

23 August 2017

5

1 reference

23 August 2017

4

1 reference

23 August 2017

213-221

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-010-0061-y

23 August 2017

0 references

cites work

In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups

1 reference

12 December 2020

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

1 reference

12 December 2020

Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de

1 reference

12 December 2020

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

1 reference

12 December 2020

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

1 reference

12 December 2020

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

12 December 2020

Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate

1 reference

12 December 2020

Treatment of chronic myeloid leukemia with imatinib mesylate

1 reference

12 December 2020

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

12 December 2020

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges

1 reference

12 December 2020

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

1 reference

12 December 2020

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

12 December 2020

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

1 reference

12 December 2020

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

12 December 2020

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

12 December 2020

Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG)

1 reference

12 December 2020

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

1 reference

12 December 2020

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

12 December 2020

Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience

1 reference

12 December 2020

Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.

1 reference

12 December 2020

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy

1 reference

12 December 2020

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

1 reference

12 December 2020

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

12 December 2020

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

12 December 2020

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

1 reference

12 December 2020

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

12 December 2020

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

1 reference

12 December 2020

Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group

1 reference

12 December 2020

Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

12 December 2020

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

1 reference

12 December 2020

Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment

1 reference

12 December 2020

1 reference

12 December 2020

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

12 December 2020

Treatment of acute lymphoblastic leukemia

1 reference

12 December 2020

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

12 December 2020

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

12 December 2020

Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing

1 reference

12 December 2020

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

1 reference

12 December 2020

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

12 December 2020

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

12 December 2020

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study

1 reference

12 December 2020

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

1 reference

12 December 2020

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

1 reference

12 December 2020

10.1007/S11899-010-0061-Y

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20652453